3 documents found, page 1 of 1
Transmural Remission Improves Clinical Outcomes Up to 5 years in Crohn's Disease
Raimundo Fernandes, S; Serrazina, J; Ayala Botto, I; Leal, T; Guimarães, A; Lemos Garcia, J; Rosa, I; Prata, R; Carvalho, D; Neves, J; Campelo, PIntroduction: Evidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavailable. Less stringent but more reachable targets such as isolated endoscopic (IER) or radiologic remission (IRR) may also be acceptable options in the long-term. Methods: Multicenter retrospective study including 404 CD patients evaluated by magnetic resonance enterography and colon...
Soluble Human Suppression of Tumorigenicity 2 Is Associated with Endoscopic Act...
Magro, F; Lopes, S; Silva, M; Coelho, R; Portela, F; Branquinho, D; Correia, L; Fernandes, S; Cravo, M; Caldeira, P; Tavares de Sousa, H; Patita, MBackground: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab. Methods: We conducted an open-label single-arm multicentre prospective study. At screening/baseline, week 6 (W6) an...
Proactive therapeutic drug monitoring of infliximab: a comparative study of a n...
Afonso, J; Lopes, S; Gonçalves, R; Caldeira, P; Lago, P; Tavares de Sousa, H; Ramos, J; Gonçalves, AR; Ministro, P; Rosa, I; Vieira, AI; Dias, CCBACKGROUND: Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time of approximately 8 h, and delaying the target dosage adjustment to the following infusion. AI...